[Clinical effect analysis of sintilimab combined with chemotherapy in the treatment of malignant pleural mesothelioma].

PubMed 2026

View at publisher
Authors: J H Zhou, X J Zhao, S J Yang
DOI: 10.3760/cma.j.cn121094-20240613-00268
Cited by: 0

Abstract

Chemotherapy+sintilimab and chemotherapy+bevacizumab are more effective than chemotherapy alone in treating malignant pleural mesothelioma, and can prolong the progression free survival of patients.

Fields of Study & Subjects

Occupational and environmental lung diseases Intraperitoneal and Appendiceal Malignancies Cancer Immunotherapy and Biomarkers

Publication details

Journal / source
PubMed
Volume
44
Issue
1
Pages
54–58
Publication date
20 January 2026
Language
ZH